Physicians and teaching hospitals may now review and dispute data on payments or other transfers of value from pharmaceutical companies, biological makers, and device makers that were reported to the Centers for Medicare and Medicaid Services (CMS) as part of the Open Payments program. All disputes must be resolved by May 15, and the data will be made available to the public beginning June 30. After the review period closes on May 15, physicians can still initiate disputes, but updated data will not be displayed until the next reporting cycle.
CMS developed the Open Payments program to comply with the Physician Payment Sunshine Act (Sunshine Act), which is part of the Affordable Care Act. The Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal health care programs to report certain payments and items of value given to physicians and teaching hospitals. CMS is required to report this information annually.
The review process is voluntary, but registration in both the CMS Enterprise Identity Management System (EIDM) and the Open Payments system is required to review the data and file disputes. APA members who have not yet registered on the Open Payments database can review our resources here.
The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising on this site. Clinical information is not peer reviewed and thus should be independently verified. Privacy Policy.
